Aspen Neuroscience, Inc. (NasdaqGS: ASPE)
Health Care · Biotechnology · US
$12.59
-7.49% today · -15.4% 1Y
Aspen Neuroscience, Inc. (NasdaqGS: ASPE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $366.10M and employs 117 people.
Over the last twelve months the share price has lost 15.4%, trading between 11.76 and 14.89.
Tweenvest scores Aspen Neuroscience, Inc. across four factors: quality 44/100, value 100/100. Its strongest factor is value.
ASPE price history
Key figures
- Market cap
- $366.10M
- Revenue (TTM)
- —
- P/E
- -7.54
- EPS
- -6.29
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $14.89
- 52-week low
- $11.76
- Avg volume (3M)
- —
- Shares outstanding
- 29.08M
- Employees
- 117
- Next earnings
- —
About Aspen Neuroscience, Inc.
Aspen Neuroscience, Inc. is a clinical-stage regenerative medicine biotechnology company, which engages in the development of autologous induced pluripotent stem cell (iPSC)-derived therapies to address neurodegenerative diseases. Its product candidate, sasineprocel, is an investigational single-dose, autologous iPSC-based cell therapy for the treatment of Parkinson's disease (PD). The company was founded by Jeanne F. Loring and Andrés Bratt-Leal in 2018 and is headquartered in San Diego, CA.
- ISIN
- US0449331091
- Founded
- 2018
- Listed since
- Oct 30, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| MapLight Therapeutics, Inc.NasdaqGS: MPLT | $369.29M | $6.57 | -4.78% |
| Puma Biotechnology, Inc.NasdaqGS: PBYI | $368.09M | $7.12 | -1.39% |
| Cuorips Inc.TSE: 4894 | $367.71M | ¥6,620.00 | 0.00% |
| CytoDyn Inc.OTCPK: CYDY | $366.94M | $0.25 | -0.20% |
| Prelude Therapeutics IncorporatedNasdaqGS: PRLD | $362.54M | $3.52 | -6.88% |
| C4 Therapeutics, Inc.NasdaqGS: CCCC | $362.44M | $2.76 | -0.36% |
| Lyell Immunopharma, Inc.NasdaqGS: LYEL | $351.57M | $14.30 | -8.57% |
| YD Bio LimitedNasdaqGM: YDES | $345.66M | $4.88 | -6.06% |